Pancreatic Cancer Research

ResearcherUniversity of GroningenActive in the last 2 years

Jeanin Elise van Hooft

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4424-0079; OpenAlex author ID A5074911126. Sources: OpenAlex.

Their work

Papers
55 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
175
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 8 papers · 2021: 4 papers · 2022: 8 papers · 2023: 3 papers · 2024: 5 papers · 2025: 6 papers · 2026: 8 papers

Papers 50 of 55

  1. Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. Co-author DOI 10.1016/j.eclinm.2026.103755↗
  2. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  3. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  4. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  5. Longitudinal body composition changes distinguish pancreatic ductal adenocarcinoma from controls in a pre-diagnostic CT cohort. Co-author DOI 10.1016/j.pan.2026.09.008↗
  6. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  7. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  8. Association Between Computed Tomography-Based AI-Derived Body Composition and Survival in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.14309/ajg.0000000000003896↗
  9. Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis. Co-author DOI 10.1007/s10689-025-00512-5↗
  10. Multimodal Pancreatic Cancer Detection Using Methylated DNA Biomarkers in Pancreatic Juice and Plasma CA 19-9: A Prospective Multicenter Study. Co-author DOI 10.1016/j.cgh.2024.07.048↗
  11. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Co-author DOI 10.1016/j.pan.2025.03.011↗
  12. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  13. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  14. Protein N-Glycosylation Traits Combined with CA19-9 Accurately Distinguish Pancreatic Cancer Cases From Healthy Controls and Benign Pancreatic Diseases. Co-author DOI 10.1097/mpa.0000000000002517↗
  15. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  16. Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer. First author DOI 10.1007/s10689-024-00368-1↗
  17. Temporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cgh.2024.03.038↗
  18. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  19. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op.23.00447↗
  20. Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecu… Co-author DOI 10.1007/s40291-022-00635-w↗
  21. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  22. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  23. Prevalence, features, and explanations of missed and misinterpreted pancreatic cancer on imaging: a matched case-control study. Co-author DOI 10.1007/s00261-022-03671-6↗
  24. A Novel Pancreatic Cancer Mini-tumor Model to Study Desmoplasia and Myofibroblastic Cancer-Associated Fibroblast Differentiation. Co-author DOI 10.1016/j.gastha.2022.04.019↗
  25. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  26. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Co-author DOI 10.1136/gutjnl-2020-323611↗
  27. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREO… Co-author DOI 10.1200/jco.21.02233↗
  28. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗
  29. Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study. Last author DOI 10.3390/cancers14174228↗
  30. Single fiber reflectance spectroscopy for pancreatic cancer detection during endoscopic ultrasound guided fine needle biopsy: a prospective cohort study. Co-author DOI 10.7150/ijms.65364↗
  31. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Co-author DOI 10.1002/ijc.33540↗
  32. Pancreatic steatosis on computed tomography is an early imaging feature of pre-diagnostic pancreatic cancer: A preliminary study in overweight patients. Co-author DOI 10.1016/j.pan.2021.01.003↗
  33. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  34. Pancreatitis and pancreatic cancer: A case of the chicken or the egg. Last author DOI 10.3748/wjg.v27.i23.3148↗
  35. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  36. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-020-00171-8↗
  37. Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. Co-author DOI 10.1016/j.pan.2020.10.032↗
  38. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  39. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  40. Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making progra… Co-author DOI 10.1177/2050640620945534↗
  41. Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled t… Co-author DOI 10.1186/s13063-020-4180-z↗
  42. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III P… Co-author DOI 10.1200/jco.19.02274↗
  43. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗
  44. Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. Co-author DOI 10.1055/a-0574-2396↗
  45. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. Co-author DOI 10.1080/02656736.2017.1401126↗
  46. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-016-9930-4↗
  47. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000725↗
  48. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Co-author DOI 10.1245/s10434-017-5900-9↗
  49. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Co-author DOI 10.1002/pon.4047↗
  50. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Co-author DOI 10.1136/gutjnl-2014-308008↗

Closest collaborators

The 25 strongest of 175 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Derk C.F. Klatte · 11 shared papers, 2022–2026 · strength 2.26
  2. Marc G. Besselink · 18 shared papers, 2016–2026 · strength 2.24
  3. Bert A. Bonsing · 14 shared papers, 2020–2026 · strength 2.19
  4. Monique Esther van Leerdam · 10 shared papers, 2022–2026 · strength 2.09
  5. Lydia G. van der Geest · 11 shared papers, 2020–2026 · strength 2.05
  6. Johanna W. Wilmink · 14 shared papers, 2017–2026 · strength 2.04
  7. Michael B. Wallace · 9 shared papers, 2021–2026 · strength 1.88
  8. Marco J. Bruno · 19 shared papers, 2011–2026 · strength 1.70
  9. Judith de Vos‐Geelen · 10 shared papers, 2020–2026 · strength 1.69
  10. Marjolein Y.V. Homs · 10 shared papers, 2020–2026 · strength 1.60
  11. Aleksander M. Bogdanski · 6 shared papers, 2024–2026 · strength 1.42
  12. Hanneke W.M. van Laarhoven · 10 shared papers, 2017–2026 · strength 1.40
  13. Ignace H. J. T. de Hingh · 9 shared papers, 2016–2026 · strength 1.38
  14. Hjalmar C. van Santvoort · 7 shared papers, 2020–2026 · strength 1.24
  15. Bas Groot Koerkamp · 10 shared papers, 2020–2026 · strength 1.22
  16. Casper H.J. van Eijck · 10 shared papers, 2016–2026 · strength 1.22
  17. J. Sven D. Mieog · 6 shared papers, 2022–2026 · strength 1.05
  18. Yan Bi · 4 shared papers, 2024–2026 · strength 1.00
  19. Martijn W.J. Stommel · 5 shared papers, 2020–2026 · strength 0.90
  20. Vincent Erwin de Meijer · 4 shared papers, 2025–2026 · strength 0.82
  21. Ingrid C. A. W. Konings · 10 shared papers, 2016–2022 · strength 0.81
  22. Izaak Quintus Molenaar · 6 shared papers, 2016–2026 · strength 0.78
  23. Lois A. Daamen · 4 shared papers, 2025–2026 · strength 0.75
  24. Lodewijk A.A. Brosens · 4 shared papers, 2022–2026 · strength 0.73
  25. Femme Harinck · 10 shared papers, 2011–2022 · strength 0.73

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.